A MEDICAMENT FOR TREATING INFLUENZA CHARACTERIZED BY COMBINING A CAP-DEPENDENT ENDONUCLEASE INHIBITOR AND AN ANTI-INFLUENZA DRUG
申请人:Shionogi & Co., Ltd.
公开号:US20200261481A1
公开(公告)日:2020-08-20
A medicament characterized in that (A) a compound represented by the formula (I):
its pharmaceutically acceptable salt, or a solvate thereof,
wherein
P is hydrogen or a group to form a prodrug;
A
1
is CR
1A
R
1B
, S or O;
A
2
is CR
2A
R
2B
, S or O;
A
3
is CR
3A
R
3B
, S or O;
A
4
is each independently CR
4A
R
4B
, S or O;
the number of hetero atoms among atoms constituting the ring which consists of A
1
, A
2
, A
3
, A
4
, nitrogen atom adjacent to A
1
and carbon atom adjacent to A
4
is 1 or 2;
R
1A
and R
1B
are each independently hydrogen, halogen, alkyl or the like;
R
2A
and R
2B
are each independently hydrogen, halogen, alkyl, or the like;
R
3A
and R
3B
are each independently hydrogen, halogen, alkyl, or the like;
R
4A
are each independently hydrogen, halogen, alkyl, or the like;
R
4B
are each independently hydrogen, halogen, alkyl, or the like;
R
3A
and R
3B
may be taken together with an adjacent carbon atom to form non-aromatic carbocycle or non-aromatic heterocycle;
n is any integer of 1 to 2; and
R
1
is
or the like,
is combined with (B) compound(s) having an anti-influenza activity, its pharmaceutically acceptable salt or a solvate thereof and/or an antibody having anti-influenza activity, is useful for treating or preventing influenza.
一种药物,其特征在于(A)由以下式(I)表示的化合物:
其药学上可接受的盐,或其溶剂合物,
其中
P为氢或形成前药的基团;
A
1
为CR
1A
R
1B
、S或O;
A
2
为CR
2A
R
2B
、S或O;
A
3
为CR
3A
R
3B
、S或O;
A
4
分别为独立的CR
4A
R
4B
、S或O;
构成由A
1
、A
2
、A
3
、A
4
、邻接到A
1
的氮原子和邻接到A
4
的碳原子的环的原子中的杂原子数为1或2;
R
1A
和R
1B
分别为独立的氢、卤素、烷基或类似物;
R
2A
和R
2B
分别为独立的氢、卤素、烷基或类似物;
R
3A
和R
3B
分别为独立的氢、卤素、烷基或类似物;
R
4A
分别为独立的氢、卤素、烷基或类似物;
R
4B
分别为独立的氢、卤素、烷基或类似物;
R
3A
和R
3B
可以与相邻的碳原子结合形成非芳香碳环或非芳香杂环;
n为1到2的任意整数; 和
R
1
为
或类似物,
与具有抗流感活性的(B)化合物,其药学上可接受的盐或其溶剂合物和/或具有抗流感活性的抗体结合,用于治疗或预防流感。